Standard Emergency Hyperkalaemia Treatment

How it works

Dosage & preparation

Preparation

Risks & contraindications

Comparisons

Highlighted claims

• Insulin and albuterol are not FDA-approved specifically for hyperkalaemia and only temporarily shift potassium into cells rather than removing it from the body. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Dextrose is given alongside insulin in the standard combination to reduce insulin-related hypoglycaemia risk, and is withheld if blood glucose is 400 mg/dL or higher. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Standardising all patients on the same initial combination therapy reduced heterogeneity and allowed a cleaner assessment of the adjunct binder effect. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• A single dose of intravenous insulin or nebulised albuterol commonly lowers serum potassium by approximately 1 mEq/L. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Loop diuretics have reduced efficacy in chronic kidney disease and have not been well studied in the emergency department setting. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department